pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Pfizer settles US Protonix lawsuit for $785m

over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

Pfizer 2014 guidance threatened by Celebrex competition

The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)
Teva defends Copaxone from Dutch patent challenge

Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal
Takeda expands Latin American footprint

These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.
Pfizer sales dip as net income surges in Q2

from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.
Teva and Sun pay dearly for 'at-risk' generic Protonix launch

The settlement marked the end of almost a decade of litigation over the intellectual property for Protonix (pantoprazole), and is the first time that generic pharma companies have been punished for ... Teva and Sun took a risk in 2007 and 2008 when they

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Pharma deals during June 2013

Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead
Interview: Trevor Smith, Takeda

For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Add my company

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...